Advertisement

The guidelines they are a changin’

Published:February 22, 2020DOI:https://doi.org/10.1016/j.ejim.2020.02.024
      The association of cancer with a clinical hypercoagulable state has been known for over 140 years but continues to be an important clinical problem. Despite rapid changes in cancer treatments, venous thromboembolism (VTE) remains associated with novel anti-cancer regimens. These include lenalidomide in multiple myeloma, immunotherapy agents in various solid tumors, cyclin dependent kinase inhibitors in breast cancer and anti-epidermal growth factor receptor antibodies in colorectal cancers [
      • Gervaso L
      • Montero AJ
      • Jia X
      • Khorana AA
      Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
      ,
      • Petrelli F
      • Cabiddu M
      • Borgonovo K
      • Barni S
      Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
      ,
      • Chakraborty R
      • Bin Riaz I
      • Malik SU
      • et al.
      Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis.
      ,
      • Roopkumar J
      • Kim AS
      • Bicky T
      • Hobbs BP
      • Khorana AA
      Venous thromboembolism in cancer patients receiving immunotherapy.
      ]. Arterial thromboembolism, although less well-studied, has also been associated with multi-targeted tyrosine kinase inhibitors such as sorafenib and sunitinib as well as immunotherapy [
      • Choueiri TK
      • Schutz FA
      • Je Y
      • Rosenberg JE
      • Bellmunt J
      Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
      ,
      • Bar J
      • Markel G
      • Gottfried T
      • et al.
      Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gervaso L
        • Montero AJ
        • Jia X
        • Khorana AA
        Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
        J Thromb Haemost. 2020; 18: 162-168
        • Petrelli F
        • Cabiddu M
        • Borgonovo K
        • Barni S
        Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
        Ann Oncol. 2012; 23: 1672-1679
        • Chakraborty R
        • Bin Riaz I
        • Malik SU
        • et al.
        Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis.
        Cancer. 2020;
        • Roopkumar J
        • Kim AS
        • Bicky T
        • Hobbs BP
        • Khorana AA
        Venous thromboembolism in cancer patients receiving immunotherapy.
        Blood. 2018; 132: 2510
        • Choueiri TK
        • Schutz FA
        • Je Y
        • Rosenberg JE
        • Bellmunt J
        Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
        J Clin Oncol. 2010; 28: 2280-2285
        • Bar J
        • Markel G
        • Gottfried T
        • et al.
        Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study.
        Eur J Cancer. 2019; 120: 122-131
        • Khorana AA
        • Dalal MR
        • Lin J
        • Connolly GC
        Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.
        Clinicoecon Outcomes Res. 2013; 5: 101-108
      1. Khorana AA, McCrae KR, Milentijevic D, et al. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. J Med Econ2020:1-7.

        • Key NS
        • Khorana AA
        • Kuderer NM
        • et al.
        Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.
        J Clin Oncol. 2019; (JCO1901461)
        • Verso M
        • Di Nisio M
        Management of venous thromboembolism in cancer patients: considerations about the clinical practice guideline update of the American society of clinical oncology.
        Eur J Int Med. 2020; 71: 4-7
        • Khorana AA
        • Soff GA
        • Kakkar AK
        • et al.
        Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer.
        N Engl J Med. 2019; 380: 720-728
        • Carrier M
        • Abou-Nassar K
        • Mallick R
        • et al.
        Apixaban to prevent venous thromboembolism in patients with cancer.
        N Engl J Med. 2019; 380: 711-719
        • Khorana AA
        • Francis CW
        • Kuderer NM
        • et al.
        Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial.
        Thromb Res. 2017; 151: 89-95
        • Verso M
        • Agnelli G
        • Barni S
        • Gasparini G
        • LaBianca R
        A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
        Intern Emerg Med. 2012; 7: 291-292
        • Li A
        • Carlson JJ
        • Kuderer NM
        • et al.
        Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.
        Cancer. 2020;
        • McBane RD
        • Wysokinski WE
        • Le-Rademacher JG
        • et al.
        Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial.
        J Thromb Haemost. 2020; 18: 411-421
        • Wang TF
        • Zwicker JI
        • Ay C
        • et al.
        The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH.
        J Thromb Haemost. 2019; 17: 1772-1778
        • Khorana AA
        • Noble S
        • Lee AYY
        • et al.
        Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
        J Thromb Haemost. 2018; 16: 1891-1894
        • Farge D
        • Frere C
        • Connors JM
        • et al.
        2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
        Lancet Oncol. 2019; 20: e566-ee81